Search

Author/Creator Clay, Timothy D

2. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Issue 1 (20th January 2023)

Authors:
Rudin, Charles M; Pandha, Hardev S; Zibelman, Matthew; Akerley, Wallace L; Harrington, Kevin J; Day, Daphne; Hill, Andrew G; O'Day, Steven J; Clay, Timothy D; Wright, Gavin M; Jennens, Ross R; Gerber, David E; Rosenberg, Jonathan E; Ralph, Christy; Campbell, David C; Curti, Brendan D; Merchan, Ja...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 11:Issue 1(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search